2020
DOI: 10.1038/s41598-020-74577-w
|View full text |Cite|
|
Sign up to set email alerts
|

Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients

Abstract: We evaluated the prognostic implications of the circulating tumor cell (CTC) count in non-metastatic, HER2-negative breast cancer patients who failed to achieve pathologic complete response (pCR) after neoadjuvant chemotherapy (NCT). A total of 173, non-metastatic breast cancer patients treated with NCT were prospectively enrolled. CTCs were obtained from blood drawn pre-NCT and post-NCT using a SMART BIOPSY SYSTEM isolation kit (Cytogen Inc., Seoul, Korea) with immunofluorescence staining. Excluding 26 HER2-p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 13 publications
(9 citation statements)
references
References 67 publications
1
8
0
Order By: Relevance
“…In our study, CTCs ≥ 5 was significantly associated with the patient outcomes as frequency of CR was less and that of death was more with CTCs ≥ 5; these results are similar to the study of Zhang et al [ 27 ] who concluded that CTCs can effectively predict TNBC recurrence and progression, which are helpful and have high values in judging and improving the prognosis. These results are supported also by Karhade et al [ 29 ] who reported that CTCs predict shorter progression-free and overall survival in TNBC cases, and Gwark et al [ 30 ] who found that patients with TNBC who failed to achieve PCR with ≥5 CTCs showed worse RFS and OS. Furthermore, CTCs could be used as an independent predictive and prognostic biomarker for MBC patients' outcomes [ 21 ] and can predict early disease recurrence and reduce the OS in patient's nonmetastatic breast cancer [ 26 ].…”
Section: Discussionsupporting
confidence: 77%
“…In our study, CTCs ≥ 5 was significantly associated with the patient outcomes as frequency of CR was less and that of death was more with CTCs ≥ 5; these results are similar to the study of Zhang et al [ 27 ] who concluded that CTCs can effectively predict TNBC recurrence and progression, which are helpful and have high values in judging and improving the prognosis. These results are supported also by Karhade et al [ 29 ] who reported that CTCs predict shorter progression-free and overall survival in TNBC cases, and Gwark et al [ 30 ] who found that patients with TNBC who failed to achieve PCR with ≥5 CTCs showed worse RFS and OS. Furthermore, CTCs could be used as an independent predictive and prognostic biomarker for MBC patients' outcomes [ 21 ] and can predict early disease recurrence and reduce the OS in patient's nonmetastatic breast cancer [ 26 ].…”
Section: Discussionsupporting
confidence: 77%
“…Recent technological advances allowed isolation and characterization of CTCs, the precursors of metastasis, and their presence in the blood of cancer patients is closely associated with poor prognosis in many tumor types, including TNBC [ 159 , 160 , 161 , 162 ]. Individual CTCs or CTC clusters in blood provide a simplified view to metastatic cascade, particularly during the spread to distant sites [ 163 ].…”
Section: Plasticity In Tnbc Progressionmentioning
confidence: 99%
“…A moderate association between detection of ≥1 CTC and positive lymph node involvement has also been reported in neoadjuvant or adjuvant patients [ 62 ]. However, other groups found no association between CTC counts and TNM stage or lymph node involvement [ 66 ]. These discrepancies may be due to the different methodologies used.…”
Section: Circulating Tumour Cell (Ctc) Analysis As a Novel Biomarker For Managing Hr+/her2− Mbc Patientsmentioning
confidence: 99%